Results suggest bispecific antibody combination could improve outcomes More: Investigational treatment shows promise for aggressive multiple myeloma Source: News
read moreIndependent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical companies from advertising directly to consumers. The End Prescription Drug Ads Now Act would prohibit drugmakers from promoting prescription drugs through
read moreMerck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease. More: Merck's Keytruda wins breakthrough
read morePfizer’s CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against
read moreZusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care. More: UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative
read moreAfter dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce. More: ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%
read more© 1994 - 2026 B.M. Pharmaceuticals